Cargando…
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncerta...
Autores principales: | Allegretti, Marcello, Cesta, Maria Candida, Zippoli, Mara, Beccari, Andrea, Talarico, Carmine, Mantelli, Flavio, Bucci, Enrico M., Scorzolini, Laura, Nicastri, Emanuele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370058/ https://www.ncbi.nlm.nih.gov/pubmed/34404919 http://dx.doi.org/10.1038/s41418-021-00844-6 |
Ejemplares similares
-
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants
por: Iaconis, Daniela, et al.
Publicado: (2022) -
The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome
por: Cesta, Maria Candida, et al.
Publicado: (2022) -
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19
por: Nicastri, Emanuele, et al.
Publicado: (2022) -
Neutrophil activation and neutrophil extracellular traps (NETs) in COVID‐19 ARDS and immunothrombosis
por: Cesta, Maria Candida, et al.
Publicado: (2022) -
Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis
por: Spera, Maria C., et al.
Publicado: (2022)